Consensus XP Inc.

Stocks

XP

KYG982391099

Investment Banking & Brokerage Services

Real-time Estimate Cboe BZX 04:10:10 28/10/26 am AEDT			5-day change	1st Jan Change
15.94 ^USD	+1.46%		-48.56%	-1.52%

27/10	Today's Biggest Movers: Brazilian Markets Shaken After Unexpected Election Results
26/10	Top Premarket Decliners	MT

Evolution of the Average Target: XP Inc.

Evolution of the Target Price: XP Inc.

Changes in Analyst Recommendations: XP Inc.

9d0098c252733617b15973.tSCX8Hq-xfoMNM5ozMnVbyYlMOkEiNbmfmFQPSAnBEQ.zX_jlgrI9ZZrRZcdpvuEOlJiYJFK34a3SFM3EEZsTA7BEqO6Fujyq2lYjw~5a6005884498dcf62b5eef0c64d1f5b6

Analysts' recommendations: XP Inc.

09/10	UBS Adjusts Price Target on XP to $37 From $25, Keeps Buy Rating	MT
07/10	XP Shares Rise After Itau BBA Upgrade	MT
06/10	Itau BBA Upgrades XP to Outperform From Market Perform, Adjusts Price Target to $27 From $19	MT
31/08	Itau BBA Upgrades XP to Outperform From Market Perform, Adjusts PT to $22 From $19	MT
03/04	UBS Adjusts Price Target on XP to $28 From $25, Maintains Buy Rating	MT
21/01	Jefferies Initiates XP at Buy With $22 Price Target	MT
17/12	UBS Adjusts XP Price Target to $25 From $23, Maintains Buy Rating	MT
17/10/25	UBS Adjusts Price Target on XP to $23 From $24, Maintains Buy Rating	MT
24/06/25	XP Shares Drop After Downgrade From Itau BBA	MT
23/06/25	Itau BBA Downgrades XP to Market Perform From Outperform, Adjusts Price Target to $21 From $20	MT
10/06/25	UBS Adjusts XP Price Target to $24 From $17, Maintains Buy Rating	MT
04/06/25	Goldman Sachs Upgrades XP to Buy From Neutral, $23 Price Target	MT
14/05/25	XP Shares Rise After Morgan Stanley Upgrades to Overweight From Equalweight	MT
13/05/25	Morgan Stanley Upgrades XP to Overweight From Equalweight, Adjusts Price Target to $24 From $18	MT
08/04/25	UBS Adjusts Price Target on XP to $17 From $16, Keeps Buy Rating	MT
18/03/25	Itau BBA Initiates XP at Outperform With $20 Price Target	MT
25/01/25	XP Shares Rise After Upgrade From UBS	MT
25/01/25	UBS Upgrades XP to Buy From Neutral, Cuts Price Target to $16 From $19	MT
11/12/24	BofA Securities Downgrades XP to Neutral From Buy, Price Target is $16	MT
26/11/24	UBS Cuts Price Target on XP to $19 From $21, Maintains Neutral Rating	MT
11/07/24	UBS Downgrades XP to Neutral From Buy, Cuts Price Target to $21 From $30	MT
05/07/24	Bradesco BBI Downgrades XP to Neutral From Outperform, Cuts Price Target to $19 From $31	MT
06/06/24	Citigroup Adjusts Price Target on XP to $27 From $29, Maintains Buy Rating	MT
01/05/24	XP Shares Decline After Goldman Sachs Downgrade	MT
30/04/24	Goldman Sachs Downgrades XP to Neutral From Buy, Cuts Price Target to $23 From $30	MT

More recommendations

Brokerage Services

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	XP INC.					+78.74%
	MORGAN STANLEY					+15.02%
	THE GOLDMAN SACHS GROUP, INC.					+15.43%
	CITIGROUP INC.					+24.52%
	CHARLES SCHWAB					+31.05%
	BANCO BTG PACTUAL S.A.					+25.51%
	CITIC SECURITIES COMPANY LIMITED					+40.02%
	EAST MONEY INFORMATION CO.,LTD.					+36.01%
	GUOTAI HAITONG SECURITIES CO., LTD.					+46.77%
	INTERACTIVE BROKERS GROUP, INC.					+29.87%
	Average					+34.29%
	Weighted average by Cap.					+23.47%